Kondo M, Cai Z, Chan C, Brown M, Reilly R
Mol Pharm. 2024; 22(1):474-487.
PMID: 39666273
PMC: 11708818.
DOI: 10.1021/acs.molpharmaceut.4c01071.
Berot A, Maniti O, El Alaoui S, Granjon T, El Alaoui M
ACS Pharmacol Transl Sci. 2024; 7(10):3034-3044.
PMID: 39416960
PMC: 11475288.
DOI: 10.1021/acsptsci.4c00197.
Hamilton E, Galsky M, Ochsenreither S, Del Conte G, Martin M, De Miguel M
Clin Cancer Res. 2024; 30(24):5548-5558.
PMID: 39405343
PMC: 11647201.
DOI: 10.1158/1078-0432.CCR-24-1513.
Lee J, Kida K, Koh J, Liu H, Manyam G, Gi Y
J Exp Clin Cancer Res. 2024; 43(1):236.
PMID: 39164784
PMC: 11337831.
DOI: 10.1186/s13046-024-03143-3.
Zakaria M, Shaharudin S, Ahmad Saad F
Eurasian J Med. 2024; 56(2):78-85.
PMID: 39145500
PMC: 11332258.
DOI: 10.5152/eurasianjmed.2024.23047.
The Performance and Clinical Applicability of HER2 Digital Image Analysis in Breast Cancer: A Systematic Review.
Dunenova G, Kalmataeva Z, Kaidarova D, Dauletbaev N, Semenova Y, Mansurova M
Cancers (Basel). 2024; 16(15).
PMID: 39123488
PMC: 11311684.
DOI: 10.3390/cancers16152761.
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.
Lei H, Ling Y, Yuan P, Yan X, Wang L, Shi Y
J Natl Cancer Cent. 2024; 3(2):121-128.
PMID: 39035731
PMC: 11256704.
DOI: 10.1016/j.jncc.2023.02.003.
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated....
Kuemmel S, Harper-Wynne C, Park Y, Franke F, De Laurentiis M, Schumacher-Wulf E
BMC Cancer. 2024; 24(1):641.
PMID: 38789924
PMC: 11127459.
DOI: 10.1186/s12885-024-12179-9.
Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa S, Suryanegara F, Setiawan D, Postma M, de Jong L
PLoS One. 2024; 19(5):e0304483.
PMID: 38787899
PMC: 11125485.
DOI: 10.1371/journal.pone.0304483.
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Lam C, Diessner B, Andrade K, Stackland S, Park L, Mehta S
J Comp Eff Res. 2024; :e230166.
PMID: 38647165
PMC: 11036880.
DOI: 10.57264/cer-2023-0166.
Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan.
Esmat E, Haidary A, Saadaat R, Rizvi S, Aleena S, Haidari M
BMC Cancer. 2024; 24(1):388.
PMID: 38539179
PMC: 10967195.
DOI: 10.1186/s12885-024-12129-5.
Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.
Rubin E, Shan K, Dalal S, Vu D, Milillo-Naraine A, Guaqueta D
Int J Mol Sci. 2024; 25(2).
PMID: 38256137
PMC: 10816365.
DOI: 10.3390/ijms25021064.
Diagnostic Accuracy of Immunohistochemistry for HER2-Positive Breast Cancer.
Thanasan S, Sukhakul K, Chitpakdee S, Kitkumthorn N
Asian Pac J Cancer Prev. 2023; 24(12):4321-4327.
PMID: 38156869
PMC: 10909106.
DOI: 10.31557/APJCP.2023.24.12.4321.
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.
Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M
J Pharm Pharm Sci. 2023; 26:12078.
PMID: 38152647
PMC: 10751338.
DOI: 10.3389/jpps.2023.12078.
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy.
Bravo M, Burgos-Molina A, Garcia-Aranda M, Redondo M, Tellez T
Cancers (Basel). 2023; 15(23).
PMID: 38067203
PMC: 10705185.
DOI: 10.3390/cancers15235499.
A multiscale model of the role of microenvironmental factors in cell segregation and heterogeneity in breast cancer development.
Romero-Arias J, Gonzalez-Castro C, Ramirez-Santiago G
PLoS Comput Biol. 2023; 19(11):e1011673.
PMID: 37992135
PMC: 10699633.
DOI: 10.1371/journal.pcbi.1011673.
Are There More HER2 FISH in the Sea? An Institution's Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry.
Suydam C, Chibane F, Brown N, Schlafly M, Arnold A, Ghleilib I
Ann Surg Oncol. 2023; 31(1):376-381.
PMID: 37936021
PMC: 10695864.
DOI: 10.1245/s10434-023-14439-7.
Circular RNAs: biology and clinical significance of breast cancer.
Wang Z, Deng H, Jin Y, Luo M, Huang J, Wang J
RNA Biol. 2023; 20(1):859-874.
PMID: 37882644
PMC: 10730165.
DOI: 10.1080/15476286.2023.2272468.
Label-Free Virtual HER2 Immunohistochemical Staining of Breast Tissue using Deep Learning.
Bai B, Wang H, Li Y, de Haan K, Colonnese F, Wan Y
BME Front. 2023; 2022:9786242.
PMID: 37850170
PMC: 10521710.
DOI: 10.34133/2022/9786242.
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials.
Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N
Mol Cancer. 2023; 22(1):159.
PMID: 37784082
PMC: 10544417.
DOI: 10.1186/s12943-023-01860-5.
